Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD
Abstract Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Physiological Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.14814/phy2.15307 |
| _version_ | 1828727783358988288 |
|---|---|
| author | Michael P. Liesen Megan L. Noonan Pu Ni Rafiou Agoro Julia M. Hum Erica L. Clinkenbeard John G. Damrath Joseph M. Wallace Elizabeth A. Swallow Matthew R. Allen Kenneth E. White |
| author_facet | Michael P. Liesen Megan L. Noonan Pu Ni Rafiou Agoro Julia M. Hum Erica L. Clinkenbeard John G. Damrath Joseph M. Wallace Elizabeth A. Swallow Matthew R. Allen Kenneth E. White |
| author_sort | Michael P. Liesen |
| collection | DOAJ |
| description | Abstract Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox‐Fgf23/Dmp1‐Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre+ mice with or without FC, thus the Dmp1‐Cre effectively reduced FGF23. Cre+ mice fed AD‐only had higher serum Pi than Cre− pre‐ and post‐diet, and the Cre+ mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL‐6 showed decreased mRNA in FC‐fed mice. The renal 1,25‐dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC‐fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC‐ and FGF23‐dependent and ‐independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit. |
| first_indexed | 2024-04-12T14:03:44Z |
| format | Article |
| id | doaj.art-d97139ec9c584ca49c400a203575d55c |
| institution | Directory Open Access Journal |
| issn | 2051-817X |
| language | English |
| last_indexed | 2024-04-12T14:03:44Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Physiological Reports |
| spelling | doaj.art-d97139ec9c584ca49c400a203575d55c2022-12-22T03:30:08ZengWileyPhysiological Reports2051-817X2022-06-011011n/an/a10.14814/phy2.15307Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKDMichael P. Liesen0Megan L. Noonan1Pu Ni2Rafiou Agoro3Julia M. Hum4Erica L. Clinkenbeard5John G. Damrath6Joseph M. Wallace7Elizabeth A. Swallow8Matthew R. Allen9Kenneth E. White10Department of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USADepartment of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USADepartment of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USADepartment of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USADepartment of Physiology Marian University Indianapolis Indiana USADepartment of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USAPurdue University Weldon School of Biomedical Engineering West Lafayette Indiana USADepartment of Biomedical Engineering Indiana University‐Purdue University at Indianapolis Indianapolis Indiana USADepartment of Anatomy, Cell Biology, and Physiology Indiana University School of Medicine Indianapolis Indiana USADepartment of Biomedical Engineering Indiana University‐Purdue University at Indianapolis Indianapolis Indiana USADepartment of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USAAbstract Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox‐Fgf23/Dmp1‐Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre+ mice with or without FC, thus the Dmp1‐Cre effectively reduced FGF23. Cre+ mice fed AD‐only had higher serum Pi than Cre− pre‐ and post‐diet, and the Cre+ mice had higher BUN regardless of FC treatment. Total serum iron was higher in all mice receiving FC, and liver Tfrc, Bmp6, and hepcidin mRNAs were increased regardless of genotype; liver IL‐6 showed decreased mRNA in FC‐fed mice. The renal 1,25‐dihydroxyvitamin D (1,25D) anabolic enzyme Cyp27b1 had higher mRNA and the catabolic Cyp24a1 showed lower mRNA in FC‐fed mice. Finally, mice with loss of FGF23 had higher bone cortical porosity, whereas Raman spectroscopy showed no changes in matrix mineral parameters. Thus, FC‐ and FGF23‐dependent and ‐independent actions were identified in CKD; loss of FGF23 was associated with higher serum Pi and BUN, demonstrating that FGF23 was protective of mineral metabolism. In contrast, FC maintained serum iron and corrected inflammation mediators, potentially providing ancillary benefit.https://doi.org/10.14814/phy2.15307CKDferric citrateGF23ironkidneyklotho |
| spellingShingle | Michael P. Liesen Megan L. Noonan Pu Ni Rafiou Agoro Julia M. Hum Erica L. Clinkenbeard John G. Damrath Joseph M. Wallace Elizabeth A. Swallow Matthew R. Allen Kenneth E. White Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD Physiological Reports CKD ferric citrate GF23 iron kidney klotho |
| title | Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD |
| title_full | Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD |
| title_fullStr | Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD |
| title_full_unstemmed | Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD |
| title_short | Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD |
| title_sort | segregating the effects of ferric citrate mediated iron utilization and fgf23 in a mouse model of ckd |
| topic | CKD ferric citrate GF23 iron kidney klotho |
| url | https://doi.org/10.14814/phy2.15307 |
| work_keys_str_mv | AT michaelpliesen segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT meganlnoonan segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT puni segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT rafiouagoro segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT juliamhum segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT ericalclinkenbeard segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT johngdamrath segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT josephmwallace segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT elizabethaswallow segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT matthewrallen segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd AT kennethewhite segregatingtheeffectsofferriccitratemediatedironutilizationandfgf23inamousemodelofckd |